Nanjing Yixinhe Pharmaceutical Technology

Nanjing Yixinhe Pharmaceutical Technology is a biopharmaceutical company headquartered in Nanjing, China, specializing in the development of high-end complex generics and improved innovative drugs. The company's primary therapeutic focus lies in chronic disease management, specifically metabolic disorders like diabetes and obesity, as well as cardiovascular and cerebrovascular diseases. Yixinhe utilizes advanced drug delivery and formulation technologies to create value-added medicines that offer better efficacy or patient convenience compared to existing treatments. Their pipeline includes late-stage candidates such as semaglutide and liraglutide formulations, alongside lipid-lowering combination therapies. The company maintains integrated R&D and manufacturing capabilities to support its goal of providing high-quality, accessible healthcare solutions.